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Abstract  
Our study examined AFC variation across the cycle and its impact on clinical 
management. We documented AFC in early (iAFC) and late follicular phase 
(sAFC) in 79 women. We examined absolute agreement between iAFC and sAFC 
as well as agreement for categorisation into categories of risk of extremes of 
ovarian response. We compared controlled ovarian stimulation (COS) protocols 
designed with iAFC and sAFC and the predictive value of iAFC and sAFC for 
extremes of ovarian response in women who underwent COS.  We found 
significant difference between iAFC and sAFC (16 [IQR 9 – 23] vs. 13 [IQR 7 – 21], 
p=0.001) with moderate agreement for the classification into at risk of extremes 
of response (k=0.525). There was good agreement for protocol selection based 
on either AFC (k=0.750) and starting gonadotrophin dose (CCC 0.970 [95% CI 
0.951 – 0.982]). iAFC and sAFC maintained good predictive value for poor 
ovarian response and risk of ovarian hyperstimulation syndrome (AUC 0.932 
[0.832 – 1.0], 0.927 [0.850 – 1.0]) and (AUC 0.701 [0.533 – 0.869], 0.737 [0.504 – 
0.971]) respectively.  AFC varies across the menstrual cycle but this does not 
have a significant impact on COS protocol design and prediction of extremes of 
ovarian response. 
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Introduction 
Assessment of the biomarkers of ovarian response is integral to the work up of 
women presenting with subfertility. Biomarkers used in routine clinical include  
anti - mullerian hormone (AMH), early follicular phase follicle stimulating 
hormone (FSH) and early follicular phase antral follicle count (AFC). AMH is the 
marker of ovarian reserve with least intracycle variability (Deb et al. 2013) 
making it the most convenient as it  can be performed at any point in the cycle 
(Iliodromiti et al. 2014). FSH is a late marker of poor ovarian response 
(Broekmans et al. 2006; Iliodromiti et al. 2014) and alone is not considered 
adequate to design a protocol of controlled ovarian stimulation (COS)  (Broer et 
al. 2013).  AFC by transvaginal ultrasound in the early follicular phase of the 
cycle continues to be part of initial investigations for women presenting with 
subfertility as the test can be easily performed directly by the treating clinician 
with immediately available results (Scheffer et al. 2002).   
 
An inherent concern with use of AFC as a biomarker is its operator dependence 
(Iliodromiti and Nelson 2015). Another concern has been timing of AFC 
determination with regard to menstrual cycle. Current recommendations limit 
AFC determination to the early follicular phase in an attempt at standardization 
(Broekmans et al. 2010). However this restriction creates anxiety for patients as 
it creates a narrow time window within which to complete their assessments 
and results in considerable administrative burden for clinics to schedule 
appointments. It also increases the number of visits for the patient  to the clinic.  
 
The aim ovarian response biomarker determination is to identify patients at risk 
extremes of ovarian response and individualize COS protocols to obtain an 
optimal result (Bosch and Ezcurra 2011). A degree of intracycle variability that 
does not jeopardize these objective may acceptable in clinical practice. Indeed 
some data on this subject exist, a retrospective study of over 3,000 patients 
argued that the clinical usefulness of AFC remains unchanged across the cycle 
(Rombauts et al. 2011). 
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The aim of our study was to examine whether AFC determination in the late 
follicular phase of the cycle would impact selection of COS protocol and the 
accuracy of AFC to predict extremes of ovarian response. 
  
Materials and Methods 
The study took place in the Reproductive Medicine Unit (RMU) of University 
College London Hospital (UCLH) between April 2014 and June 2015. We sought 
the opinion of the Joint Research Office of the hospital and were advised that 
formal ethics approval was not required as the project involved no change in 
routine clinical practice.  
 
We included women with a regular 28 – 34 day cycle referred for fertility 
investigation. All women referred to the clinic undergo a transvaginal ultrasound 
scan between days 2 to 5 of their menstrual cycle for examination of the pelvis, 
uterus and assessment of the AFC (Voluson E8 Expert, GE Medical Systems, Zipf, 
Austria). All women undergo a second ultrasound examination on day 8 – 12 of 
their cycle for Hysterosalpingo – Contrast - Sonography (HyCoSy) or 3D saline 
infusion sonohysterography (3D SIS). At the second examination the ovaries are 
routinely examined and a repeat AFC is performed. Determination of the antral 
follicle count is performed according to internationally agreed guidance 
(Broekmans et al. 2010).  Briefly,  we identify each ovary and examine it in two 
planes to determine its limits. We then sweep the complete ovary in the 
transverse plane to identify and count all follicles 2 – 10mm in diameter. 
Abdominal pressure is applied in cases of difficult visualization. All examinations 
were performed by three operators (DM, AA, and VT).  
 
Further routine investigations in our unit for women with subfertility are serum 
AMH (Beckman Coulter AMH Gen II ELISA) and day 2 -5 FSH determinations. 
AMH and FSH results were archived on a database which is not accessed during 
ultrasound examinations thereby blinding operators to these results.  
 
We created a spreadsheet (Excel 11 for Mac, Microsoft Corp.) to record the 
women’s demographic details, day of the cycle the first examination took place 
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and the early follicular phase AFC (iAFC) in each ovary.  We created a second 
spreadsheet to document the day of the cycle the second examination took place 
and the late follicular phase AFC (sAFC) in each ovary as well as  the presence 
and mean diameter of a dominant follicle in either ovary. Once all examinations 
were complete the databases were amalgamated and the AMH and FSH results 
were added.  
 
We used the National Instute of Clinical Exellence (NICE) fertility guideline to 
define categories of “at risk of low response”, “normal response” and “at risk of 
high response”  after COS (NICE 2013) i.e.: i)total AFC ≤4 and ≥16  ii) AMH 
≤5.4pmol/l and ≥25.0 respectively. We classified women into the various 
categories based on each of AMH, iAFC and sAFC. 
 
During the study we excluded women with amenorrhea or irregular cycles as we 
would not be able to time AFC determination, women with known pathologies 
such as endometriosis or large fibroids that displace the ovaries and affect the 
accuracy of AF counts. We also excluded women over 40 years old, those with a 
BMI>30 and those who did not tolerate HyCoSy or 3D SIS examination.   
 
In order to examine the interobserver variability in AFC determination in our 
unit, a set of ovarian 3D volumes were obtained by DM and AA from a different 
cohort of patients and stored. The volumes were anonymised and each operator 
was asked examine the volumes and record the total AFC for each woman in 
individualized Excel spreadsheets. Each operator was blind to other operators’ 
findings. 
 
COS protocols in our unit are individualized according to age, body mass index 
(BMI), AMH, AFC, FSH and clinician preference (Bosch and Ezcurra 2011). To 
further explore the potential impact of performing AFC in the late follicular 
phase criteria we created two Excel spreadsheets with clinical and ORT data for 
each case. Both spreadsheets contained age, AMH,FSH and a total AFC value. One 
spreadsheet contained the iAFC and the other sAFC. The cases were arranged in 
random order and there were no  identifiers. EY was blinded as to whether the 
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spreadsheet contained iAFC or  sAFC and was asked to select a COS protocol. The 
protocols we routinely use include : (i) long agonist, (ii) long agonist with 
withdrawal of GnRHa on day 3 of stimulation, (iii) antagonist and (iv) no COS. EY 
also selected starting dose of gonadotrophin dose (human menopausal 
gonadotrphin, hMG) for each case.  
 
For  women who underwent a COS cycle we collected data on IVF protocol, total 
gonadotrophin dose, serum oestradiol concentration at trigger and the total 
number of oocytes retrieved.  We classified women who had ≤4 oocytes retrieved 
as “poor response” and ≥16 oocytes retrieved as “at risk of ovarian 
hyperstimulation syndrome (OHSS)”. 
 
Statistical analysis 
 
Interobserver variability was assessed by calculating Lin’s concordance 
correlation coefficient (CCC), plotting Bland – Altman plots and calculating the 
absolute and relative limits of agreement (LoA) between observers. To assess 
agreement between iAFC and sAFC we calculated Lin’s CCC, plotted Bland – 
Altman charts and calculated LoA. To examine the impact of AFC timing on i) 
classification into categories of predicted response to COS and ii) on COS 
protocol selection we constructed 2xn tables to calculate Cohen’s κ for category 
agreement between iAFC and sAFC. To further assess the impact of AFC timing 
on COS protocol selection we calculated the CCC for gonadotrophin starting dose 
in COS protocols designed based on iAFC and sAFC. To assess the diagnostic 
value of iAFC, sAFC and AMH for the identification of poor responders to COS and 
those at risk of OHSS we constructed receiver operating curves (ROC) and 
calculated the area under the curve (AUC). We used SPSS for statistical analysis. 
(SPSS statistics, ver. 22, IBM. Corp.) 
 
Results 
Inter-observer variability 
During the study period bilateral 3D ultrasound ovarian volumes were collected 
from 24 women.  There was good or very good interobserver agreement for off -
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line AFC determination. The CCC for total AFC determination between DM and 
AA was 0.967  (95% CI 0.926 – 0.985) and 0.992 (95% CI 0.983 – 0.996) between 
DM and  VT.  The LoA for DM and AA was between -6.7 and 8.6 or -14%/6% of 
the mean AFC. The LoA for DM and VT was between -1.5 and 4.0 or -5%/14% of 
the mean AFC (Figure 1 and 2).  
 
iAFC and sAFC agreement 
During the study period 103 women under underwent both early and late 
follicular phase total AFC determination by one of the observers. 24 women were 
excluded because the interval between examinations was >6 months. The 
median age of women participating in the study was 35 years (IQR 32 – 38). The 
median day of the cycle for iAFC determination was day 4 (range 2 – 5). The 
median day of the cycle for sAFC determination was day 9 (8 – 11).  The median 
number of cycles between iAFC and sAFC was 1 (IQR  0 – 3)  
 
There was a significant difference between median iAFC and median sAFC (16 
AFC [IQR 9 – 24] vs. 13 AFC [IQR 7 – 21], p=0.001).  There was moderate 
agreement between iAFC and sAFC for categorization into predicted low 
response, normal response and risk of high response (kappa = 0.525). 54/79 
(68.4%, 95% CI 58.2 – 78.7) patients were allocated into the same categories by 
iAFC and sAFC (Table 1).  
 
The iAFC and sAFC showed moderate CCC (0.678, 95% CI 0.543 – 0.779) with 
32.2% variation in AFC within the same subject between different cycle phases.  
A Bland Altman plot showed a mean difference between measurements of 2 
(95% CI 0.63 – 4.0) with LoA between -13 and 17.  There was significant 
inequality of variance between women with <13 follicles and the rest (p=0.002) 
(Figure 3). The LoA in women with fewer follicles was -6 to 6 compared to -14 to 
21 in those with more follicles.  
 
In the blinded protocol design exercise there was good agreement between COS 
protocol types selected based on iAFC and those based on sAFC (kappa = 0.750).  
There was good agreement for starting gonadotrophin dose between COS 
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protocols designed based on iAFC and sAFC with a CCC of 0.970 (95% CI 0.951 – 
0.982). 
 
41/80 women underwent a stimulated IVF cycle. The median total hMG was 
2700 iu/L  (IQR 1462.5 – 4275) and the median number of oocytes retrieved was 
12 (IQR 6 – 15).   There was a significant positive correlation between iAFC, 
sAFC, AMH and the number of oocytes retrieved. 4/41 women (9.8%, 95% CI 0.7 
– 18.9) had ≤4 oocytes retrieved and 7/41 (17.1%, 95% CI 5.6 – 28.6) had ≥16 
oocytes retrieved. The AUC for prediction of poor response and risk of OHSS for 
age, FSH, AMH, iAFC and sAFC is shown in Table 2.  
 
Discussion 
Our study aimed to examine whether performing AFC determination in the late 
follicular phase would have an impact on the clinical management of infertile 
women.  Our results showed that there is a statistically significant difference 
between AFCs determined in the early follicular and those determined in the late 
follicular phase which leads to poor agreement between them. However this 
poor agreement does not appear to have a significant impact on COS protocol 
design and the predictive value of late follicular phase AFC for extremes of 
ovarian response. 
 
Our study is the first to prospectively examine AFC variation in a population of 
infertile women which lends validity to our findings. Previous studies have 
examined the intra cycle variation of AFC in healthy volunteers. Deb et al. 
performed a study on 38 women scanned at 4 different instances in the same 
cycle. They employed sonoAVC in a relatively young population (mean age 28 
years) and found minimal AFC intra cycle variation, in the order of 6% (Deb et al. 
2013). In contrast, van Disseldorp et al. in an older population of patients 
(median age 33 years) report an approximately 30% intra cycle AFC variation 
(van Disseldorp et al. 2010).  This level of intra cycle variation led van Disseldorp 
et al. to conclude that restricting AFC to the early follicular phase would improve 
reliability of the test. Our results are similar to those by van Disseldrop et al. and 
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we confirmed that AFCs show significant variation reaching 30% between early 
and late follicular phases of the cycle.  
 
In contrast to van Disseldopr et al. in our study the majority of paired AFC 
measurements were not performed in the same cycle but consecutive cycles but 
never more than 6 cycles apart. While this interval restriction ensures that the 
observed effect reflects inter and intra cycle variation rather than underlying age 
related decline, it is not possible to discern directly from our results whether the 
variation we observed is due to intra or inter cycle change. This would require 
examinations in the same cycle followed by examinations in a subsequent cycle  
which may be difficult to achieve. Others have examined the inter cycle variation 
of early follicular AFCs  and both Elter et al. and Bancsi et al. showed that AFC 
exhibits significant inter cycle variability with the coverage interval of the 
difference ranging to a minimum of +/- 6 follicles (Bancsi et al. 2004; Elter et al. 
2005) . Compared to these authors we observed greater limits of agreement 
between paired AFCs which may be due to our population’s considerably higher 
median AFC.  When we restricted the population to women with less than total 
13 follicles the limits of agreement in our study were identical to those previous 
reports ( +/- 6). This is despite the fact the determinations happened in different 
cycle times.  From this it would appear that two AFCs determined in different 
cycles and different times in the cycle are not more variable than AFCs 
determined in different cycles at the same cycle time.   
 
One of the purposes of biomarkers of ovarian response is to alert clinicians to the 
risk of poor ovarian response to stimulation and, at the other end of the 
spectrum, the risk of high response leading to OHSS. In this study we wanted to 
examine whether the degree of AFC variation we and others have observed 
would impact this categorisation. Indeed, we found only moderate agreement 
between iAFC and sAFC for classification into ovarian reserve categories. The 
majority of discrepancy appears in the classification into “at risk of high 
response” category where 11 patients considered “at risk of high response” with 
early follicular AFC  would have been classified as “normal” by sAFC. It is 
questionable however whether restriction to the early follicular phase would 
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have addressed this issue as it may represent intercycle variability rather than 
intracycle variability and thus an inherent limitation of AFC. ORT is also used to 
design treatment protocols for ovarian stimulation during an IVF cycle. (Broer et 
al. 2013; Jayaprakasan et al. 2012).  We showed here that using AFC determined 
in the late follicular phase for the purpose of designing a COS protocol would not 
have lead to a change in either type of protocol selected or starting 
gonadotrophin dose. Finally it appears that AFC timing does not impact the 
predictive ability of the test for extremes of response at the time of COS with 
both iAFC and sAFC showing a similar area under the curve for the prediction of 
poor response and risk of OHSS. This is consistent with the retrospective study 
by Rombauts et al. showing that the AFC retains its predictive ability irrespective 
of the time in the cycle it was determined (Rombauts et al. 2011). 
 
AFC as a test of ovarian reserve has been criticized for substantial operator 
dependency (Iliodromiti et al. 2014) . Nevertheless authors have shown that 
there is adequate interobserver agreement for AFC determination using both 3D 
and 2D transvaginal ultrasound (Scheffer et al. 1999). We aimed to produce a 
pragmatic study and so did not restrict the operators  included. In order to 
assess the robustness of our results, we examined the reliability of AFC 
determination in our unit.  In agreement with Sheffer et al. we demonstrated 
excellent ICC between operators included in this study suggesting that the AFC 
variation we observed represents a real difference rather than inter observer 
variability.  
 
One of the reasons the current consensus restricts AFC timing to days 2 - 5  of the 
cycle is an attempt to standardize AFC measurements (Broekmans et al. 2010). 
However women dislike being scanned while menstruating and achieving this 
timing creates unnecessary administrative burden for the clinic. Transvaginal 
scanning provides a wealth of information beyond AFC and will remain an 
integral part of infertility assessment. However the greater cycle stability and 
operator independence of AMH suggest that AFC will become a complementary 
test rather than a main ORT determinant. We show here that AFCs determined in 
different cycle phases have significant statistical difference but  similar clinical 
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validity. Based on our results it may be possible to combine AFC determination 
in the late follicular phase with other ultrasound based tests such as 3D SIS and 
HyCoSy without significant loss of clinically useful information.   
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  sAFC    
  Low 
response 
Normal 
response 
High 
response 
Total 
iAFC Low response n (%) 2    
(66.6) 
1    
(33.3) 
0 3 
 
 Normal response n (%) 5     
(13.9) 
27 
(75.0) 
4    
(11.1) 
36 
 High response n (%) 0  11  
(27.5) 
29 
(72.5) 
40 
 
Table 1: Agreement between iAFC and sAFC for categorization into at risk of low 
response (total AFC ≤4), normal and at risk of high response (total AFC≥16)   (k = 
0.525) 
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 Area under the curve (95% CI) 
 Poor 
response 
 Risk of OHSS  
iAFC 0.932 (0.857 – 1.0) 0.701 (0.533 – 0.869) 
sAFC 0.927 (0.850 – 1.0) 0.737 (0.504 – 0.971) 
AMH 0.880 (0.762 – 0.998) 0.691 (0.485 – 0.898) 
FSH 0.625 (0.334 – 0.917) - - 
Age 0.720 (0.509 – 0.931) - - 
 
Table 2 Area under the curve for the prediction of poor response (oocytes ≤4) 
and risk of OHSS (oocytes≥16) after COS using a variety of ovarian response 
biomarkers (n=41) 
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